CYLD Antibody (YA7085)

Cat. No.: HY-P87397: Data Sheet User Guide for Antibodies
FAQs
Technical Support

CYLD Antibody (YA7085) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CYLD.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

CYLD Antibody (YA7085) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CYLD.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Predicted band size: 107.3kDa;

Species Reactivity

Human

SwissProt ID

Q9NQC7

Immunogen

Purified recombinant fragment of human CYLD (AA: 204-358) expressed in E. Coli.

Application &
Dilution Ratio

Application	Dilution Ratio
FC FC: Flow Cytometry	1:200-1:400
ELISA ELISA: Enzyme Linked Immunosorbent Assay	1:10000

Sensitivity	Endogenous	Purity	affinity purified.
Conjugation	Non-conjugated	Modification	Unmodified
Isotype	IgG1

Appearance

Liquid

Formulation

Supplied in PBS with 0.05% sodium azide

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-alpha-induced necroptosis (PubMed:18313383, PubMed:18636086, PubMed:26670046, PubMed:26997266, PubMed:27458237, PubMed:27591049, PubMed:27746020, PubMed:29291351, PubMed:32185393). Negatively regulates NF-kappa-B activation by deubiquitinating upstream signaling factors (PubMed:12917689, PubMed:12917691, PubMed:32185393). Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation (PubMed:12917690). Negative regulator of Wnt signaling (PubMed:20227366). Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules (PubMed:19893491). Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis (PubMed:18222923, PubMed:20194890). Required for normal cell cycle progress and normal cytokinesis (PubMed:17495026, PubMed:19893491). Inhibits nuclear translocation of NF-kappa-B (PubMed:18636086). Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation (PubMed:18636086). Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells (By similarity). Negatively regulates TNFRSF11A signaling and osteoclastogenesis (By similarity). Involved in the regulation of ciliogenesis, allowing ciliary basal bodies to migrate and dock to the plasma membrane; this process does not depend on NF-kappa-B activation (By similarity). Ability to remove linear ('Met-1'-linked) polyubiquitin chains regulates innate immunity and TNF-alpha-induced necroptosis: recruited to the LUBAC complex via interaction with SPATA2 and restricts linear polyubiquitin formation on target proteins (PubMed:26670046, PubMed:26997266, PubMed:27458237, PubMed:27591049). Regulates innate immunity by restricting linear polyubiquitin formation on RIPK2 in response to NOD2 stimulation (PubMed:26997266). Involved in TNF-alpha-induced necroptosis by removing linear ('Met-1'-linked) polyubiquitin chains from RIPK1, thereby regulating the kinase activity of RIPK1 (By similarity). Negatively regulates intestinal inflammation by removing 'Lys-63' linked polyubiquitin chain of NLRP6, thereby reducing the interaction between NLRP6 and PYCARD/ASC and formation of the NLRP6 inflammasome (By similarity). Does not catalyze deubiquitination of heterotypic 'Lys-63'-/'Lys-48'-linked branched ubiquitin chains (PubMed:27746020). Removes 'Lys-63' linked polyubiquitin chain of MAP3K7, which inhibits phosphorylation and blocks downstream activation of the JNK-p38 kinase cascades (PubMed:29291351). Also removes 'Lys-63'-linked polyubiquitin chains of MAP3K1 and MA3P3K3, which inhibit their interaction with MAP2K1 and MAP2K2 (PubMed:34497368)

Subcellular Localization：Cytoplasm,Cytoplasm, perinuclear region,Cytoplasm, cytoskeleton,Cell membrane,Cytoplasm, cytoskeleton, microtubule organizing center, centrosome,Cytoplasm, cytoskeleton, spindle,Cytoplasm, cytoskeleton, cilium basal body

Expression：
Tissue_Specificity: Detected in fetal brain, testis, and skeletal muscle, and at a lower level in adult brain, leukocytes, liver, heart, kidney, spleen, ovary and lung. Isoform 2 is found in all tissues except kidney

Isoforms & Post-Translational Modification：Q9NQC7 has two isomers: Q9NQC7-1: 107316 Da (predicted); Q9NQC7-2: 107044 Da (predicted).
Ubiquitinated丨Phosphorylated on several serine residues by IKKA and/or IKKB in response to immune stimuli

Subunit：Interacts (via CAP-Gly domain) with IKBKG/NEMO (via proline-rich C-terminal region) (PubMed:12917689, PubMed:12917690, PubMed:12917691, PubMed:15341735)

Database

SwissProt: SwissProt: Q9NQC7

Documentation

User Guide for Antibodies (1077 KB)